Targeted Medical Pharma

TRGM · OTC

$0.00+$0.00 (+600.00%)TodayMarket open · · Delayed 15 min
No price history for this range.

About TRGM

Targeted Medical Pharma, Inc. is a medical nutrition company, which engages in the research, development, and commercialization of amino acid-based medications. The company is headquartered in Los Angeles, California. The company went IPO on 2012-09-10. The firm is engaged in developing amino acid based medical foods and other oral nutrition products for the long-term management of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep, respiratory disorders, allergies and cognitive disorders. The company manufactures eight amino acid based medical foods along with the dietary supplements, which include Grotrexa, AppTrim, Hypertensa Advanced and Clearwayz. Its Targeted Cellular Technology is a patented formulation that allows reduced concentrations of amino acids and other ingredients in the milligram range to stimulate the production of neurotransmitters to treat the nutritional deficiencies associated with certain diseases and conditions. The Company’s medical food brands include Theramine, Trepadone, Percura, GABAdone, Sentra PM, AppTrim-D and Sentra AM.

Employees
0
Headquarters
Los Angeles, California
Listed
Sep 10, 2012
Sector
Health Care
Industry
Pharmaceuticals

TRGM key statistics

Market cap
211
Price-earnings ratio
—
Dividend yield
—
Average volume
400
Volume
2.90K
Open price
$0.00
High today
$0.00
Low today
$0.00
52 Week high
$0.0246
52 Week low
$0.00

Targeted Medical Pharma (TRGM) at a glance

As of May 14, 2026, Targeted Medical Pharma (TRGM) shares are priced at $0.00, giving the company a market cap of 211.

Volume so far is 2.90K shares, above the average of 400 shares a day.

Over the past year Targeted Medical Pharma has ranged from $0.00 to $0.0246, and now sits 0% of the way up that range.

Targeted Medical Pharma met or beat analyst EPS estimates in 1 of the last 3 quarters. In Q3 FY14 it reported -$0.04 per share against an estimate of $0.00.

TRGM earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 3 quarters, by 2.0% on average.

  1. Q1 FY14: reported -$0.04 per share against an estimate of -$0.0204
  2. Q2 FY14: reported -$0.02 per share against an estimate of -$0.0204
  3. Q3 FY14: reported -$0.04 per share against an estimate of $0.00

Similar companies

Companies in the same industry as Targeted Medical Pharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.